anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study was to investigate the impact of vaginal delivery on adverse pregnancy outcomes after cesarean section for the cicatricial uterus. Eighty patients with scarred uterus after cesarean section admitted to our hospital from October 2019 to May 2021 were selected for the study. Among them, 44 cases were eligible for vaginal delivery. Thirty-eight cases of cesarean delivery were selected as the control group and 42 cases of vaginal delivery were selected as the observation group according to the mode of delivery. Baseline data, 24-h blood loss, length of hospital stay, hospital costs, 5-minute Apger score, and adverse pregnancy outcomes were compared between the two groups. When comparing the age, gestational age, number of pregnancies, and duration of cesarean delivery between the two groups (t = 1.333, 0.989, 0.597, 0.752, P > 0.05), the scar thickness in the observation group was higher than that in the control group. The 24-h postpartum bleeding and hospitalization cost was lower in the observation group than in the control group, the hospitalization time was shorter than in the control group, and the 5-minute Apger score was higher than in the control group (t = 21.744, 15.029, 11.524, 7.342, P < 0.05). The incidence of maternal and neonatal complications was compared between the two groups (23.68% vs 7.14%, 7.89% vs 0.00%, correction 2 = 1.083, 1.605, P > 0.05). The incidence of adverse pregnancy outcomes was 7.14% in the observation group, which was significantly lower than the 31.57% in the control group. The difference was statistically significant (correction 2 = 4.060, P < 0.05).
A chitosan coating solution which is so safe that it is capable of oral administration in the fields of foods and medicines; a chitosan coating film reduced in the content of a residual organic acid and having satisfactory water resistance; and a coated medical preparation having the coating film. The coating solution is  characterized by  being obtained by incorporating a glycerin fatty acid ester into an aqueous chitosan solution prepared through dissolution with a volatile organic acid. The chitosan coating film is one obtained by drying and solidifying the solution through film coating. The organic acid used in the dissolution remains in the coating film only in a small amount and the film has satisfactory water resistance. When the chitosan coating solution, which contains a glycerin fatty acid ester and is a highly safe solution prepared through dissolution with a volatile organic acid, is subjected to film coating, a film is formed and, simultaneously therewith, the organic acid continuously volatilizes. Consequently, a chitosan coating film having water resistance can be efficiently obtained. Furthermore, by forming a known enteric coating film in combination with the coating film on the outer side thereof, an application to large-intestine drug delivery system preparations can be expected with ease.
Desmopressin Acetate is also available as nasal spray and tablet dosage forms. 

When switching between formulations, the below text is meant as guidance for starting dose. However, dose should always be titrated individually according to the diuresis (antidiuretic response) and electrolyte status (serum sodium) of the patient. 

When switching from Desmopressin Acetate Nasal Spray to Desmopressin Acetate Injection, the starting dose is one-tenth times the Desmopressin Acetate Nasal Spray dose.

When switching from Desmopressin Acetate Tablets to Desmopressin Acetate Injection, titrate dose individually according to the diuresis (antidiuretic response) and electrolyte status (serum sodium) due to the large variability in both PK and PD. Monitor patients closely during the initial dose titration period.
In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
The invention relates to a peptide-based conditioner and a colorant for hair, skin and nails. Peptides have been identified to have high binding affinity to hair, skin, and nails. The invention describes a peptide-based hair conditioner, a hair colorant, a skin conditioner, a skin colorant, and a nail colorant. The peptide-based hair conditioner and the hair colorant consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring agent, respectively. The peptide-based skin conditioner and the skin colorant consist of a skin-binding peptide coupled to a skin conditioning agent or a coloring agent, respectively. The peptide-based nail colorant consists of a nail-binding peptide coupled to a coloring agent. In all these compositions, the peptide can be directly coupled to an active agent, or the coupling can be via a spacer. The invention also describes personal care compositions containing these peptide-based conditioners and colorants.
The present invention provides for compositions, methods and kits for regulating energy metabolism. In one aspect, the invention provides for compositions that comprise a combination of (a) branched chain amino acids, such as leucine, and (b) vitamin B6, or any precursors or metabolites of (a) or (b). These combinations may be synergistic and/or effective for reducing weight or adipose volume. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising branched chain amino acids and vitamin B6. The invention also provides for kits comprising compositions of branched chain amino acids and vitamin B6 packaged in an oral dose form with usage instructions. WO 2013/134736 PCT/US2013/030044 u~ E~cc ua ua (4 o- r - c quilses uoilasue:)+
PURPOSE OF REVIEW: Healthcare-associated infections (HAIs) represent a major burden on healthcare facilities. Effective infection prevention strategies are essential to prevent the spread of HAIs. These can be broadly classified as vertical and horizontal interventions. Through this review, we aim to assess the merits of these strategies.
RECENT FINDINGS: Vertical strategies include active surveillance testing and isolation for patients infected or colonized with a particular organism. These strategies are beneficial to curb the spread of emerging pathogens and during outbreaks. However, the routine use of contact precautions for organisms such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus remains controversial. Horizontal interventions are larger-scale and reduce HAIs by targeting a common mode of transmission shared by multiple organisms. Among these, hand hygiene, chlorhexidine gluconate bathing of select patients and environmental decontamination are the most high-yield and must be incorporated into infection prevention programs. As antimicrobial stewardship is also an effective horizontal strategy, antimicrobial stewardship programs must operate in synergy with infection prevention programs for maximal impact.
SUMMARY: Overall, horizontal interventions are considered more cost-effective and have a broader impact. Infection control programs may opt for a combination of vertical and horizontal strategies based on local epidemiology and available resources.
FIELD: medicine, organic chemistry, pharmacy. SUBSTANCE: invention relates to development of novel medicinal preparations inhibiting proliferation of lymphocytes. Invention proposes the novel biologically active compound 2-amino-6-(1-ethyl-2-methyl-4- nitroimidazolyl-5)-thiopurine inhibiting proliferation of lymphocytes. 2-Amino-6-(1-ethyl-2-methyl-4- nitriomidazolyl-5)-thiopurine inhibits the primary immune response of animals for thymus-depending and thymus- nondepending antigens effectively. These preparations can be used in practical medicine for carrying out immunodepressive and antileukosis therapy. EFFECT: new compound indicated above, enhanced effectiveness, expanded therapeutic action. 3 dwg
The present invention relates to herbal medicine powder and concentrate for prevention from viral infection before the onset of lung disease, and to a storage container thereof. Specifically in the present invention, an inner space of the storage container is separated into two, so that one container stores a powder and the other container contains concentrate, and thus the powder and concentrate can be used as food whenever a user wants to eat and drink. The recent outbreak of lung disease viruses such as SARS, MERS, and Corona has developed into a pandemic (warning measure issued by the World Health Organization when a disease is pandemic), and people around the world are living in fear and pain, and some people lose their lives. However, it is a helpless repetition of daily life that has no choice but to wait until a vaccine for a degenerative virus is developed. The present invention has been devised to solve the above-described problems, and has a purpose of providing the powder and concentrate, in which by drying medicinal herbs among herbal medicines, edible ones are made into powders, and by boiling, drinkable concentrates are made into liquids and stored in a separate container to be put when making rice or soup, adding when drinking tea, and making as a pill. In addition, an objective of the present invention is to provide the storage container that prevents the powder or liquid from being deformed for a long time and always maintains a state thereof.
The invention relates to a traditional Chinese medicine for treating acute mastitis, and belongs to the field of traditional Chinese medicine formulas. The medicine is characterized by being prepared from the following raw materials in parts by weight: 15-25 g of angelica dahurica, 15-20 g of scutellaria baicalensis, 10-15 g of fritillaria, 10-15 g of fructus forsythiae, 10-15 g of honeysuckle and 10 g of liquorice. The preparation method comprises the steps of putting the Chinese herbal medicines such as the dahurian angelica root, the baical skullcap root, the fritillary bulb, the weeping forsythia, the honeysuckle, the liquorice and the like in proportion into a decoction container, and adding cold water, wherein the water is preferably 2-3 cm higher than the medicines. Soaking for 30 min to make it thoroughly soaked, so as to facilitate decoction. Then boiling with strong fire, decocting with slow fire to 200 ml, removing residue and collecting decoction. Decocting for 2 times a day, and taking orally 1 time in the morning and evening respectively, and covering with quilt to take slight sweat. The invention has the characteristics of easily obtained materials, simple preparation, low cost, high cure rate and no toxic or side effect.
This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where prevalence of CSP expression is high. Approximately 12 to 24 patients will be enrolled in the Dose Escalation Stage; the total number of patients will depend on the dose level at which the RP2D is defined. Patients who meet the eligibility criteria during Screening will enter the treatment period. ZB131 will be given via IV every week. Patients will be treated until disease progression or unacceptable toxicities occur.

Once the RP2D has been established, the Dose Expansion stage will begin to enroll subjects by cohort. For each expansion cohort, subjects will be enrolled in two stages. The first stage includes an evaluation of 12 patients. If 1 or more of 12 patients have a CR or PR, then accrual will continue until a total of 37 patients with measurable disease have been enrolled. Additional patients may be added to ensure 37 subjects with measurable disease are available for evaluation
The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
This is a randomized (assigned study drug by chance), double-blind (both the patient and investigator do not know whether patient is assigned to receive study drug or placebo), placebo-controlled study involving overweight and obese patients. Patients are randomized to one of 4 treatment groups and receive study drug or placebo for a period of 12 weeks. The study consists of 3 phases: a pretreatment phase (including a screening period of 1 week and a period prior to active treatment of 4 weeks), the treatment period of 12 weeks, and a posttreatment phase (consisting of a follow-up visit). Standardized nonpharmacologic therapy (individualized calorie deficit diets containing no more than 30% calories from fat and nutritional counseling) will be administered from Week 4 through the follow-up period. During the treatment period, patients visit the center every two weeks. On each visit, patients come to the clinic after 8 hours fasting. For effectiveness assessments, patients will be weighed and BMI calculated at each visit; waist and hip circumference and DEXA measurements (for body composition and fat mass analysis) will be performed at selected time points. Additional effectiveness assessments from a blood sample include levels of fasting hemoglobin type A1c (HbA1c), glucose, cholesterol, triglycerides, insulin, C-peptide, and gastrointestinal hormones. Insulin sensitivity and pancreas function are evaluated. Safety evaluations, including incidence of adverse events, clinical laboratory results, vital signs, and electrocardiograms, are performed during the study. Patients complete a questionnaire related to stomach/bowel symptoms (GI) throughout the study. Blood samples will also be drawn for an analysis of the subjects genes and an analyses of the body's handling of the study drug. The overall duration of the study for each patient is approximately 19 weeks. The study hypothesis is that treatment with JNJ-16269110 (R256918) will cause a change in body weight compared to placebo and will be well tolerated in overweight and obese patients. This hypothesis will be investigated at each dosage level to determine a clinically relevant dose. 5 mg capsules, 10 mg capsules, 15 mg capsules, or matching placebo capsules taken orally.
FIELD: cosmetics, pharmacology. SUBSTANCE: all ingredients are packed into the same container. The process is carried out or in layers throughout the whole surface of its bottom, or in part of said surface throughout the whole height of said container. Ratio of said ingredients is (1:8)-(3:1). EFFECT: improved efficiency of desired composition. 7 cl
The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production. The substances identified by the method according to the invention are particularly suited for treating IgE-induced allergies and IgE-dependent autoimmune diseases.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to microbiology, and can be used to suppress the growth of microorganisms in an aquatic environment. To this end, a synergistic microbiocidal composition containing two components is used. First component is a nonionic surfactant with the structure: RO(CHCH(CH)O)(CHCHO)H, in which Rdenotes a Cs-alkyl group. Second component is phenoxyethanol. Ratio of the weight of the nonionic surfactant to the weight of phenoxyethanol ranges from 1:1 to 1:18.2766. Synergistic composition is also used, the first component of which is a nonionic surfactant having the structure: RO(CHCH(CH)O)(CHCHO)H, in which Rdenotes a mixture of linear C-C-alkyl groups and n is 5 or 7. Second component is phenoxyethanol. In this case, the ratio of the weight of the nonionic surfactant to the weight of phenoxyethanol ranges from 1:0.1999 to 1:36.5897.EFFECT: group of inventions allows to effectively inhibit the growth of microorganisms.10 cl, 13 tbl
Lichen planus, a chronic immune-mediated inflammatory disease affects the skin and mucous membranes. Oral lichen planus is the mucosal counterpart of cutaneous lichen planus. It was reported first described in 1866 as white papular eruptions in the oral cavity. The prevalence of OLP varies from 0.1% to 4%. OLP mostly occurs in middle aged and elderly patients, with female to male ratio of 3:2. OLP is characterized by lesions consisting of radiating white, grey, velvety, thread-like papules in a linear, annular and retiform arrangement forming typical lacy, reticular patches, rings and streaks. The lesions are most common on buccal mucosa, tongue, lips, gingiva, floor of mouth, palate. Clinically OLP has six clinical presentations namely reticular, erosive, atrophic, plaque-like, papular, bullous.

Reticular form, the most common clinical form presents as fine, asymptomatic intertwined lace-like pattern called "Wickham striae" in a bilateral symmetrical form. It mainly involves the posterior mucosa of the cheek. Erosive OLP represents symptomatic lesions. Atrophic lesions may resemble the combination of two clinical forms, such as the presence of white striae characteristic of the reticular type surrounded by an erythematous area. Plaque-like form mainly found on dorsum of the tongue and the mucosa of the cheek reveals whitish homogeneous irregularities similar to leukoplakia. Papular form presents with small white papules with fine striae in its periphery. Bullous form is the most unusual clinical form, exhibiting blisters that increase in size and tend to rupture, leaving the surface ulcerated and painful.

The pathogenesis of the disease is characterized by cytotoxic CD8+ T lymphocytes migration to the epithelium inducing apoptosis of basal keratinocytes. A number of etiological factors in OLP have been proposed such as local and systemic inducers of cell-mediated hypersensitivity, drugs, dental materials, infectious agents, and stress. The existence of a local cell-mediated immune disorder has been postulated as a factor underlying development of the lesions specifically, a delayed cellular hypersensitivity response probably triggered by some exogenous agent. Periodontal diseases are the most prevalent oral microbial infections that lead to chronic inflammation of the supporting tissues of teeth. Periodontal disease has a complex pathogenesis involving host microbiome interactions. It has an impact on both local and systemic health. The pathogenesis of periodontal disease involves a local inflammatory reaction and the activation. Thus, it is possible to speculate that some interference could exist and that the potential effect arising from these shared mechanisms⁄ mediators could be localized to sites where OLP lesions are present and alteration of host immune response in OLP may have an impact on periodontal health. With this consideration, the present study is aimed to assess periodontal status in systemically healthy individuals with and without oral lichen planus.
The present invention relates to crystallizable compositions and crystals of BAFF. In addition, this invention relates to the high resolution structure of a BAFF polypeptide as obtained by X-Ray crystallography. This invention also relates to a computer (machine) comprising a machine-readable data storage medium comprising a data storage material enconded with machine-readable data comprising the structure coordinates provided by this invention. This invention also relates to methods of using the structure coordinates of BAFF  to solve the structure of similar or homologous molecules or molecular complexes and methods of determining the homology model of a similar or homologous molecule, such as APRIL. This invention also provides a computer capable of producing a three-dimensional representation of APRIL based on the homology model structure coordinates. This invention also relates to methods using the structure coordinates of BAFF to design chemical entities or compounds, including agonists or antagonists, with improved properties (such as increased or decreased binding affinity for (BAFF). This invention also provides variants of BAFF. This invention also relates to compositions comprising said chemical entities, compounds, including agonists or antagonists of BAFF, or variants.
PURPOSE: To obtain a coated granule useful for preparing a preparation unit enabling the continuous sustained release of a medicine in a therapeutically effective level in a patient by coating a granule with an ethylcellulose or methacrylic acid methyl ester, a plasticizer and an agent for preventing sticking. CONSTITUTION: This sustained releasing preparation unit is sustained releasing coated granules coated with a composition containing 2-20% (W/V) ethylcellulose or methacrylic acid methyl ester, 0.1-5.0% plasticizer (e.g. a castor oil, propylene glycol), and 0.5-20% agent for preventing sticking (e.g. magnesium stearate, a talc). By mixing the granules with at least one viscous agent, preferably 2 viscous agents, the granules are formed as a preparation unit such as a tablet. As the viscous agent, a methylcellulose, a hydroxypolymethylcellulose, a povidone, and a hydroxypropylcellulose are used and blended in rations of 2-30wt.% primary viscous agent and 0-30wt.% secondary viscous agent in the preparation unit.
The usual strategy for detecting hypertension-repeated office blood pressure (BP) measurements-is inefficient and inaccurate. When paired with ambulatory BP monitoring (ABPM), which takes a multitude of measurements over 24 hours, it is clear that office BP measurements may convey a falsely positive diagnosis known as white-coat hypertension. What is less well-known is that office BP measurements may also convey a falsely negative diagnosis termed masked hypertension (MH). That is, office BP may measure as normal, yet 24-hour ambulatory measurements show elevated BP. People with MH have cardiovascular risk that is similar to that of people with diagnosed hypertension, yet MH goes unrecognized, and therefore, untreated. Ultimately, identifying the best strategy for accurately detecting hypertension is vital to improving overall BP control and reducing cardiovascular events. Without a feasible ABPM strategy, MH will continue to go unrecognized and untreated.

Participants enrolled in the study will be randomized to either the usual care group or the ABPM-guided group. All participants will have a baseline ABPM. ABPM will be used to make a diagnosis and determine anti-hypertensive treatment in the ABPM-guided group only. Participants in the ABPM-guided group will have a follow-up ABPM in 2 months. All participants will have a final ABPM 4 months after enrollment.